Prevalence of depression and anxiety in patients with cystic fibrosis and parent caregivers: results of The International Depression Epidemiological Study across nine countries by Quittner, A. L. et al.
Article
Prevalence of depression and anxiety in patients with 
cystic fibrosis and parent caregivers: results of The 
International Depression Epidemiological Study across 
nine countries
Quittner, A. L., Goldbeck, L., Abbott, Janice, Duff, A., Lambrecht, P., 
Sole, A., Tibosch, M. M., Bergsten Brucefors, A., Yuksel, H., 
Catastini, P., Blackwell, L., Barker, D., Besier, T., Verhaak, C., 
Merkus, P., Cebrian, M., Yilmaz, O., Cowperthwaite, C., Sumner, C., 
Hurley, Margaret Anne, De Rijcke, K., Huse, D., Buzzetti, R., 
Monzon, A. and Saez-Flores, E.
Available at http://clok.uclan.ac.uk/11305/
Quittner, A. L., Goldbeck, L., Abbott, Janice, Duff, A., Lambrecht, P., Sole, A., Tibosch, M. M., 
Bergsten Brucefors, A., Yuksel, H. et al (2014) Prevalence of depression and anxiety in patients 
with cystic fibrosis and parent caregivers: results of The International Depression 
Epidemiological Study across nine countries. Thorax, 69 (12). pp. 1090­1097. ISSN 0040­6376  
It is advisable to refer to the publisher’s version if you intend to cite from the work.
http://dx.doi.org/10.1136/thoraxjnl-2014-205983
For more information about UCLan’s research in this area go to 
http://www.uclan.ac.uk/researchgroups/ and search for <name of research Group>.
For information about Research generally at UCLan please go to 
http://www.uclan.ac.uk/research/ 
All outputs in CLoK are protected by Intellectual Property Rights law, including
Copyright law.  Copyright, IPR and Moral Rights for the works on this site are retained 
by the individual authors and/or other copyright owners. Terms and conditions for use 
of this material are defined in the http://clok.uclan.ac.uk/policies/
CLoK
Central Lancashire online Knowledge
www.clok.uclan.ac.uk
Prevalence of depression and anxiety in patients with cystic fibrosis and parent caregivers: 
Results of The International Depression Epidemiological Study (TIDES) across Nine Countries 
 
Author Affiliations: 
 
1) Alexandra L. Quittner PhD 
 Affiliation: Department of Psychology & Pediatrics, University of Miami, Coral Gables FL 
2) Lutz Goldbeck PhD 
 Affiliation: Department of Child and Adolescent Psychiatry/Psychotherapy, University Hospital 
Ulm, Ulm, Germany 
3) Janice Abbott PhD 
 Affiliation: School of Psychology, University of Central Lancashire, Preston, UK 
4) Alistair Duff PhD 
 Affiliation: Department of Clinical and Health Psychology, Leeds Teaching Hospitals NHS Trust, 
UK 
5) Patrick Lambrecht MD 
 Affiliation: Department of Clinical and Lifespan Psychology, Free University Brussels, Brussels, 
Belgium 
6) Amparo Solé MD, PhD 
 Affiliation: Adult CF and Lung Transplant Unit .University Hospital la Fe, Valencia, Spain 
7) Marijke M Tibosch, PhD 
 Affiliation: Department of Medical Psychology, Radboud University Nijmegen Medical Centre, 
Nijmegen, The Netherlands 
8) Agneta Bergsten Brucefors PhD 
 Affiliation: Stockholm CF Centre, Karolinska University Hospital Huddinge, Karolinska institute, 
Stockholm, Sweden 
9) Hasan Yuksel MD 
 Affiliation: Celal Bayar University, Medical Faculty, Dept. of Pediatric Allergy and Pulmonology, 
Manisa, Turkey 
10) Paola Catastini PhD 
 Affiliation: CF Center Meyer Hospital, Pediatric Department, Florence University, Florence 
11) Laura Blackwell PhD 
 Affiliation: Department of Psychiatry, Children's Hospital Boston, Boston, MA 
12) Dave Barker PhD 
 Affiliation: Department of Psychiatry and Human Behavior, Brown University, Providence, RI 
Corresponding Author 
Alexandra L. Quittner PhD 
University of Miami 
5665 Ponce de Leon Blvd 
Coral Gables, FL 33146 
aquittner@miami.edu 
phone: +1 305 284-6932 
Summary 
Background:  Individuals with chronic diseases and parent caregivers are at increased risk for 
symptoms of depression and anxiety. Prevalence of psychological symptoms was evaluated in 
adolescents and adults with cystic fibrosis (CF) and parent caregivers across nine countries. 
Predictors of symptomatology, comorbidity of psychological distress, and concordance between 
parents and adolescents were analyzed. 
 
Methods:  Patients with CF, ages 12 and older, and caregivers of children with CF, birth to18, 
completed measures of depression and anxiety measures across 154 CF Centers in Europe and 
the US. Psychological symptoms were compared across countries using X
2
. Logistic regression 
examined extent of comorbid symptoms, predictors of depression and anxiety, and concordance 
between parent and adolescent symptomatology.  
 
Findings: Psychological symptoms were reported by 6,088 patients with CF and 4,102 parents. 
Elevated symptoms of depression were found in 10% of adolescents, 19% of adults, 37% of 
mothers, and 31% of fathers. Elevations in anxiety were found in 22% of adolescents, 32% of 
adults, 48% of mothers and 36% of fathers. Overall, elevations were 2-3 times the rates in 
community samples. Analyses of comorbid symptoms indicated that adolescents reporting 
depression were 14·97 times more likely to report anxiety; adults elevated on depression were 
13·64 times more likely to report anxiety; mothers with elevated depression were 15·52 times 
more likely to report anxiety; fathers with elevated depression were 9·20 times more likely to 
report elevated anxiety. Significant differences were found by patient age (depression: 
adolescents 19% vs. adults 29%; anxiety: adolescents 22% vs adults 32%). Mothers reported 
more symptoms of depression and anxiety than fathers, respectively (depression 37% vs. 31%; 
anxiety 48% vs. 36%).  Predictors were identified: 1) patients (female, older, lower FEV1 and 
BMI, on IVs, listed for transplant, hemoptysis/pneumothorax, psychiatric medications or 
psychotherapy; 2) parents (younger child, on IVs, psychiatric medications or psychotherapy). 
Concordance between 1122 parent-teen dyads indicated that adolescents were 2·32 and 2·22 
times more likely to be elevated on depression and anxiety, respectively, if a parent was elevated. 
 
Interpretations: Symptoms of depression and anxiety were elevated in both patients with CF 
and parents across several European countries and the US. Health variables were significantly 
related to psychological symptoms. Annual screening of psychological symptoms is 
recommended for both patients and parents.  
 
Funding: Cystic Fibrosis Foundation; Mukoviszidose Institut gGmbH, Dutch Cystic Fibrosis 
Organization (NCFS), Spanish Cystic Fibrosis Federation (FEFQ), CF Italian Foundation grant, 
UK CF Trust, The Belgian CF Association 
 
 
 
 
 
Introduction 
Meta-analyses and systematic reviews have indicated that children and adults with chronic 
diseases, as well as parent caregivers, are at increased risk for depression and anxiety.
1,2,3 
Cystic 
fibrosis (CF) is the most common genetic, life-limiting chronic disease among Caucasian 
populations and requires a treatment regimen that takes between two and four hours per day.
4
 
Patients have genetic mutations that affect the CF transmembrane conductance regulator protein, 
leading to thick mucus secretions, repeated infections and progressive failure of most organ 
systems (e.g., lungs, pancreas, and digestive, reproductive).
5
 Although recent advances in 
diagnosis and treatment have led to increases in lifespan, CF continues to be one of the most 
difficult chronic conditions to manage.
6
 
 
Studies evaluating depression and anxiety in patients with CF have generally found a high 
prevalence of psychological distress. Rates of depression in children and adolescents have 
ranged from 9-29%, using different methods of assessment (ICD-9 diagnoses, CDI).
7,8
 For adults 
with CF, rates of depression have ranged from 13-30%
9,10
 and rates of anxiety from 30% to 
33%.
9,11
 Among parent caregivers, elevations in psychological distress have also been found, 
with depression ranging from 20-35%.
7,12,13
 Overall, psychological symptoms appear to be 
higher in this population than community samples;
14
 however, these studies have been limited by 
small sample sizes and different screening or diagnostic tools, which have made interpretation of 
the results difficult. In addition, the majority of studies have only assessed symptoms of 
depression but not anxiety. 
 
Psychological distress in patients with CF has been associated with a number of negative 
consequences and health outcomes, including worse adherence,
7,15
 worse pulmonary 
function,
11,16
 increased hospitalizations and health care costs,
17
 and decreased health-related 
quality of life.
9,10
 A recent study
17
 compared adolescents with CF who had been diagnosed with a 
depressive disorder to a matched sample of non-depressed teens with CF, and found that those 
who were depressed were three times more likely to be hospitalized for a pulmonary 
exacerbation and incurred much higher health care costs over two years ($280,000 for the 
depressed group vs. $60,116 for the non-depressed group).  Given both the wide range of 
prevalence estimates for patients with CF and their caregivers, and the negative impact these 
symptoms have on disease management and functioning, the TIDES (The International 
Depression Epidemiological Study) international study group aimed to screen depression and 
anxiety in several European countries and the United States. Two screening measures were 
utilized to assess these symptoms in both adolescents and adults with CF and parent caregivers. 
Predictors of psychological symptoms, both demographic and medical, were also identified. 
 
 
Methods 
Procedure  
This study was conducted at 154 CF centers in nine countries: Belgium, Germany, Italy, Spain, 
Sweden, The Netherlands, Turkey, United Kingdom, and the United States. Screening was 
initiated in patients aged 12 through adulthood and in parents of children birth to 18 years of age. 
Study protocols were approved by national and local ethics committees or institutional review 
boards at all CF centers.  
 
Staff members approached participants at routine, stable clinic visits. After completion of 
consent/assent, patients or parents completed a basic demographic questionnaire in addition to 
the screening measures. When both parents were present, they completed the symptom measures 
independently. Depression and anxiety screening measures were scored immediately by trained 
staff members to identify clinically elevated scores; referrals were provided if necessary. 
Completion of the measures took approximately 15 minutes. Medical data were collected 
through chart review.  
 
 
 
 Participants 
Across nine countries, 1286 adolescents (M age = 14·84, SD = 1·69) and 4739 adults (M age = 
28·87, SD 9·5) with CF were screened. Inclusion criteria were: 1) confirmed diagnosis of CF, 2) 
age within specified range, and 3) screening during stable clinic visit. Patients who had received a 
solid organ transplant were excluded. In addition, 3127 mothers and 975 fathers of younger 
children reported on their own symptoms. Descriptive demographic and medical data are 
presented in Table 1. 
 
 
Measures 
Demographic and medical characteristics. Parents and young adults completed a Background 
Information Form assessing parent and child/adolescent’s age, gender, and education. 
Information about pharmacological and psychological treatment of depression and anxiety was 
also collected. Indicators of physical health status in the past six months were recorded from 
medical charts (FEV1% predicted, height, weight, hemoptysis/pneumothorax, IV antibiotics, and 
listed for transplant). 
 
Hospital Anxiety and Depression Scale.
18
 The HADS is a 14-item instrument; seven questions 
measure depression and seven measure anxiety. It has extensive reliability and validity data, and 
was designed specifically for patients with chronic medical conditions (i.e., removal of somatic 
items). Respondents indicated the severity of each symptom on a 4-point rating-scale (0-3) over 
the past week. Maximum score is 21; participants were categorized using established cutoff 
scores (mild = 8-10, moderate =11-15, severe = >16). Validated translations were used in 
Europe. 
 
Center for Epidemiological Studies-Depression Scale.
19
 The CES-D is a well-established self-
report measure of depressive symptomatology for community samples. It has 20 items measuring 
symptoms of depression that reflect diagnostic criteria on the DSM-IV and has correlated well 
with diagnostic interviews. Items are rated on a 4-point scale from 0 to 3, with higher scores 
indicating more depressive symptoms. The maximum score is 60, with ≥ 16 = elevated. Valid 
translations were used in Europe. 
 
Statistical Analyses 
Statistical analyses. Demographic and prevalence estimates were stratified by country to test for 
differences. Prevalence estimates were based on published cut-scores
18,19
 and divided into two 
groups according to “caseness:” 1) non-case (below cut-off) and 2) case (mild-severe 
symptoms).  Effect sizes were calculated to assess variability across strata: Cramér’s V(φc)  for 
categorical and eta-square (η2) for continuous variables. Logistic regression identified comorbid 
symptoms within individuals and predictors of elevated symptoms. Regression analyses were 
pooled across countries, with country of origin as a categorical covariate to account for the 
nesting of participants within countries. Missing data occurred because countries did not collect 
data for a particular question or participants did not provide a response. Amount of missing data 
was small, ranging from 0% to 7% depending on the measure. Separate analyses were run for 
each characteristic. Concordance between 1130 parent-adolescent dyads was evaluated with 
logistic regression. All analyses were run using SAS 9·3. 
 
Role of the funding source. The funding sources had no involvement in the in study design; 
collection, analysis, and interpretation of data; in the writing of the report; and in the decision to 
submit the paper for publication. The corresponding author confirms she had full access to all the 
data in the study and had final responsibility for the decision to submit for publication. 
 
Results 
 
Demographics. Demographic and health information for patients and caregivers are presented in 
Table 1 and reported by country in Table 2. On average, patients were in their mid-20’s, about 
half were female, BMI was in the normal range, and lung function indicated moderate disease 
severity. Significant variability was found across countries on age, gender, BMI, and FEV1% 
predicted, however these effects were small. Across countries, hemoptysis/pneumothorax (2-
32%), currently on IV antibiotics (5-19%), listed for transplant (2-12%), and 
pharmacological/psychological treatment of depression or anxiety (3-23%).  
 
Prevalence of Symptoms of Depression. Rates of depression varied depending on age and the 
screening tool: adolescents 5-19%, adults 13-29%, mothers 20-34%, and fathers 18-25%  (Table 
1 and Figure 1). Analyses by country indicated that overall, 11% of patients were elevated on the 
HADS-D (range 8-15%) and 27% of patients were elevated on the CES-D (range 20%-31%) 
(Table 2). Because the sample size for Turkey was small and the availability of standard 
medications for CF is limited, their estimates were not included in the ranges above (i.e., 
depression on the HADS-D=29%, CES-D=52%). Statistically significant differences were found 
by age (see Table 1), with adolescents reporting fewer symptoms of depression than adults (19% 
vs. 29% on the CES-D; p<.001).  Mothers reported significantly more depressive symptoms than 
fathers on the CES-D (34% vs. 25%; p<.001), but not on the HADS-D (20% vs. 18%). 
 
For the countries that administered both the HADS-D and CES-D to patients, significant 
differences in prevalence rates were found between measures.  Adolescents were 5·32 (p <·01) 
and adults were 2·24 (p <·01) times more likely to report elevated symptoms of depression on 
the CES-D than the HADS-D. For parents, mothers were 2·15 (p <·01), and fathers 1·57 (p <·01) 
times more likely to report elevations on the CES-D than the HADS-D. 
 
Prevalence of Symptoms of Anxiety. Symptoms of anxiety were prevalent in patients and parents: 
adolescents 22%, adults 32%, mothers 48%, and fathers 36% (see Table 1 and Figure 1). 
Analyses by country indicated high rates of anxiety among patients (mean 30%), with moderate 
variability across countries (14%-35%; Turkey falls within this range). Statistically significant 
differences were found by age, with 22% of adolescents vs. 32% of adults (p<·001) reporting 
elevations in anxiety above the cutoff score (see Table 1, Figure 1). Mothers also reported 
significantly more symptoms of anxiety than fathers (48% vs. 36%, p<·001).    
 
Comorbidity between depression and anxiety. Adolescents reporting depression were 14·97 
times more likely to also report anxiety, with 6% reporting elevations in both. For adults the odds 
ratio was 13·64, with 14% reporting both depression and anxiety. Mothers reporting depression 
were 15·52 times more like to also report anxiety, with 31% reporting both and for fathers the 
odds ratio was 9.20, with 21% reporting both depression and anxiety. All effect sizes were large. 
 
Predictors of depression and anxiety. Logistic regressions indicated that, for adolescents, the 
following characteristics were associated with elevated symptoms of depression on the CES-D or 
HADS-D: being female (Odds Ratio [OR] = 1·77), an episode of hemoptysis/ pneumothorax in 
past six months (OR= 3·82), taking psychiatric medication for depression or anxiety (OR = 
3·96), and receiving psychotherapy for depression or anxiety (OR = 6·54; Table 3). 
Characteristics associated with elevated anxiety were: being female (OR = 1·63), episode of 
hemoptysis/pneumothorax in past six months (OR=2·03), recently on IV antibiotics (OR = 1·73), 
taking psychiatric medications (OR=1·91), and receiving psychotherapy (OR=2·77).  
 
For adults, depression was associated with: older age (OR=1·02 per year), lower FEV1% 
predicted (OR=0·90 per 10% change), hemoptysis or pneumothorax in past six months 
(OR=1·62), recently on IV antibiotics (OR=1·65), listed for transplant (OR=1·39), taking 
psychiatric medications (OR=3·56), and receiving psychotherapy (OR=3·21). Characteristics 
associated with elevated symptoms of anxiety were: older age (OR=1·02 per year), being female 
(OR=1·66), lower BMI (OR=1·03 per unit), lower FEV1 (OR =0·96 per 10% change), 
hemoptysis/pneumothorax (OR=1·38), listed for transplant (OR=1·34), taking psychiatric 
medications (OR=3·37), and receiving psychotherapy (OR=4·22). 
 
For mothers, child characteristics associated with depression were: recently on IV antibiotics 
(OR=1·53) and receiving psychotherapy (OR=1·88). Elevated anxiety was associated with: 
younger age (OR= 1·03 per year), recent IV antibiotics (OR=1·52), and receiving psychotherapy 
(OR=2·02). For fathers, only one child medical variable was associated with depression: recent 
IV antibiotics (OR=1·72).  
 
Concordance between parent and adolescent depression and anxiety. For the 1122 dyads with 
both parent and teen report, adolescents were 2·39 times more likely be above the cut-off for 
depression if at least one of their parents had elevated symptoms and they were 2·22 times more 
likely to be above the cut-off for anxiety if their parent was also elevated.  
 
Discussion 
 
This is the largest psychological screening study to date conducted in a rare disease, with data 
collected from both European countries and the US. Results across nine countries revealed high 
rates of depression and anxiety in adolescents and adults with CF, as well as parent caregivers. 
Elevated depression was reported by 17% of patients across countries, regardless of which 
screening tool was used—a rate two times that reported in community populations (9·2%).20 
Similarly, although there are fewer large-scale studies of caregivers, 37% of mothers and 31% of 
fathers reported clinically elevated depression, which is three times the rate in community 
samples.
20,21
 Rates of anxiety were also elevated in patients and caregivers, with 30% of patients 
and 36-48% of parents above the clinical cut-off. These rates are approximately twice those 
reported in the community.
22
    
 
Given these high rates of psychological symptoms and their documented effects on disease 
management, including clinic attendance and adherence to prescribed treatments,
23
 annual 
screening of depression and anxiety for adolescents and adults with CF and parent caregivers is 
warranted. This conclusion is consistent with several international guidelines, which recommend 
regular screening for adolescents and adults with chronic conditions—particularly if these 
symptoms impact daily functioning and management of the disease.
24–28
 For example, the 
American Diabetes Association recommends screening of psychological symptoms at “regular 
clinical encounters” and when there is “concern about poor management”28 To date, however, 
there is no guideline recommendation for screening parent caregivers. 
 
As found in prior studies, comorbidity of depressive and anxious symptoms within individuals 
was high, suggesting that elevations in depression confer a heightened risk of elevations in 
anxiety.  Analyses of parent-adolescent dyads showed that depression or anxiety in either parent 
doubled the risk that the adolescent would report elevated psychological distress. In addition to 
parents’ reporting elevated symptoms in this large study, co-occurrence of symptomatology 
provides a second rationale for screening parent caregivers. Identification and treatment of 
parental psychological distress may both prevent adolescents with CF from developing 
psychological symptoms and when detected in parents, prompt the medical team to provide 
referrals for mental health services to the family. 
 
We utilized two well-established screening measures of depression, and in countries that used 
both, comparisons indicated that the HADS-D under-estimated symptoms of depression by a 
factor of two. Recent studies comparing the HADS-D and PHQ-9 for the purposes of large-scale 
screening concluded there were significant psychometric problems with the HADS, including 
lack of sensitivity and a three, rather than two-factor structure.
20,29 
A comparison of items on the 
HADS-D and CES-D revealed that many of the diagnostic criteria in the DSM-IV/5 were not 
represented on the HADS-D (e.g., cognitive impairment, lack of energy). Instead, the vast 
majority of items on the HADS-D measured anhedonia (72%), whereas the CES-D included 
items representing the full spectrum of depressive symptoms underlying this construct.  
 
Several risk factors were associated with elevated depression and anxiety. Older age and female 
sex, worse disease severity, as indicated by lower lung function or BMI ,and recent changes in 
health status (past six months), such as hemoptysis or prescription of IV antibiotics. Treatments 
for psychological distress (with medication or psychotherapy) were the highest risk factors. For 
parents, recent course of IV antibiotics, and current treatment for a psychological disorder were 
associated with greater symptomatology.  
 
Limitations and Future Directions 
Although the demographic and health information from the three largest samples in this study 
(UK, US and Germany) appeared quite similar to data in their respective national registries,
12,16
 it 
is possible that this sample is not representative of the larger international population.  In 
screening studies, those who are experiencing the most severe symptoms are less likely to attend 
regular clinic visits or give informed consent for participation in research, and thus, these 
prevalence rates may be an underestimate of the population.
30
 This study was also limited by the 
cross-sectional nature of the data collection. Prospective, longitudinal studies are needed to 
determine: which health variables predict increases in psychological symptoms and what health 
consequences follow identification of elevated scores (e.g., decreased adherence, increases in 
pulmonary exacerbations, increases in healthcare utilization and cost, decreases in health-related 
quality of life). 
 
These results highlight the importance of measuring and treating mental health issues in patients 
and families coping with serious, chronic illnesses. Our findings, in conjunction with other 
smaller studies, have led to the formation of an international committee, sponsored by both the 
European Cystic Fibrosis Society and the Cystic Fibrosis Foundation, to develop guidelines on 
mental health screening and treatment in CF. As advocated by other national guidelines 
committees, we have recommended annual screening of depression and anxiety in adolescents 
and adults with CF and parent caregivers.
25–28
 Our goal is to implement these screening 
recommendations, utilizing the unique structure of accredited and recognized CF centers in 
Europe and the US, to promote their implementation.  
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Table 1· Participant Characteristics by Respondent 
 
 
 Respondent 
 
Adolescent Adult 
Effect 
Size 
P-
Value Mothersa Fathersa 
Effect 
Size  
P-
Value 
Sample size 1286 4739   3127 975   
Age, mean (SD), years 14·84 (1·69) 28·87 (9·54) ·31 <·01 8·90 (5·08) 8·52 (5·14) <·01     ·04 
Female 669 (53%) 2271 (48%) ·03 <·01 1558 (50%) 460 (47%)   ·03     ·08 
BMI, mean (SD) 19·54 (3·11) 21·87 (3·54) ·07 <·01 17·47 (2·99) 17·28 (2·92) <·01     ·10 
FEV1 percent predicted, 
mean (SD) 83·78 (23·44) 62·32 (24·51) ·12 <·01 89·23 (21·55) 90·74 (22·13) <·01     ·12 
Hemoptysis or 
pneumothorax in six months 35 (3%) 657 (14%) ·14 <·01 37 (1%) 9 (1%) <·01     ·84 
Currently on IV antibiotics 156 (12%) 733 (16%) ·03   ·04 299 (10%) 118 (12%)   ·04     ·02 
Listed for transplant 7 (1%) 243 (5%) ·09 <·01 12 (0·4%) 1 (0·1%)   ·02     ·23 
Currently on psychiatric 
medication for dep/anx 44 (4%) 466 (10%) ·09 <·01 59 (2%) 9 (0·9%)   ·03     ·11 
Currently receiving 
psychotherapy for dep/anx 70 (6%) 379 (8%) ·03   ·03 103 (3%) 19 (2%)   ·02     ·23 
Positive Scores     Caregivers 
HADS-D 60 (5%) 609 (13%) ·11 <·001 618 (20%) 173 (18%)   ·02     ·16 
CES-D 87 (19%) 488 (29%) ·09 <·001 1057 (34%) 240 (25%)   ·08 <·001 
Either HADS-D or CES-D 130 (10%) 913 (19%) ·10 <·001 1165 (37%) 305 (31%)   ·05 <·001 
HADS-A 281 (22%) 1503 (32%) ·09 <·001 1496 (48%) 343 (36%)   ·11 <·001 
  Notes: a Characteristics of younger patients whose parents completed the screening   
 

Table 3· Univariate logistic regression results 
  Respondent 
 
 
Adolescent  Adult   Mother  Father 
  Odds Ratio (95% CI) p - value  Odds Ratio (95% CI) p - value  Odds Ratio (95% CI) p - value  Odds Ratio (95% CI) p - value 
H
A
D
S
 o
r 
C
E
S
D
 D
ep
re
ss
io
n
 
Age, years 1·01 (0·89-1·13) 0·96  1·03 (1·02-1·04) **<·01  0·99 (0·98-1·01) ·32  0·99 (0·96-1·01) ·30 
Female 1·77 (1·17-2·66) *0·01  1·09 (0·94-1·26) ·28  0·95 (0·81-1·10) ·47  0·93 (0·70-1·23) ·61 
BMI 1·03 (0·98-1·10) 0·26  1·01 (0·99-1·03) ·27  1·01 (0·98-1·03) ·70  1·03 (0·99-1·09) ·17 
FEV1 percent predicted 
a 0·98 (0·90-1·06) 0·62  0·90 (0·88-0·93) **<·01  1·00 (0·96-1·04) ·97  0·95 (0·88-1·03) ·20 
Hemoptysis/pneumothorax 
in last six months 
3·82 (1·63-8·95) **<·01  1·62 (1·33-1·98) **<·01  0·96 (0·47-1·97) ·92  1·29 (0·31-5·34) ·72 
IV antibiotics* 1·74 (0·94-3·21) 0·08  1·65 (1·33-2·04) **<·01  1·53 (1·17-2·01) **<·01  1·72 (1·12-2·63) *·01 
Received an organ 
transplant b 
-- --  1·39 (1·03-1·87) *·03  1·10 (0·31-3·85) ·88  -- -- 
Currently on psychiatric 
medication for dep/anx 
3·96 (1·94-8·08) **<·01  3·56 (2·86-4·42) **<·01  1·51 (0·88-2·61) ·14  0·68 (0·14-3·33) ·63 
Currently receiving 
psychotherapy for dep/anx 
6·54 (3·56-12·01) **<·01  3·21 (2·54-4·06) **<·01  1·88 (1·25-2·83) **<·01  0·52 (0·15-1·84) ·31 
H
A
D
S
 A
n
x
ie
ty
 
Age, years 0·99 (0·91-1·07) ·79  1·02 (1·01-1·03) **<·01  0·98 (0·97-1·00) *·03  0·98 (0·95-1·00) ·08 
Female 1·63 (1·23-2·15) **<·01  1·66 (1·46-1·88) **<·01  0·94 (0·81-1·09) ·40  0·83 (0·63-1·09) ·17 
BMI 0·99 (0·95-1·04) ·79  1·03 (1·01-1·05) **<·01  0·99 (0·97-1·02) ·50  0·98 (0·94-1·03) ·53 
FEV1 percent predicted 
a 1·01 (0·95-1·07) ·76  0·96 (0·93-0·98) **<·01  0·99 (0·95-1·03) ·54  0·99 (0·91-1·06) ·71 
Hemoptysis/pneumothorax 
in last six months 
2·03 (0·99-4·14) *·05  1·38 (1·15-1·65) **<·01  1·32 (0·67-2·58) ·42  0·82 (0·20-3·44) ·79 
IV antibiotics* 1·73 (1·13-2·66) *·01  1·14 (0·94-1·37) ·18  1·52 (1·16-1·98) **<·01  1·10 (0·71-1·71) ·67 
Received an organ 
transplant b 
-- --  1·34 (1·01-1·77) *·04  0·91 (0·29-2·90) ·88  -- -- 
Currently on psychiatric 
medication for dep/anx 
1·91 (1·00-3·68) *·05  3·37 (2·74-4·14) **<·01  0·97 (0·57-1·65) ·92  0·64 (0·16-2·63) ·54 
Currently receiving 
psychotherapy for dep/anx 
2·77 (1·65-4·62) **<·01  4·22 (3·37-5·30) **<·01  2·02 (1·32-3·09) **<·01  2·03 (0·79-5·17) ·14 
Notes: a Odds ratios are for a 10% change in FEV1 percent predicted. 
 bVariable was not included in the model for 12-18 year olds due to small number of cases. 
 
Figure 1· Rates of depression and anxiety by respondent 
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